Vita
Wissenschaftliche Stationen
- Juli 2024: Galenus Privatstiftung Gastprofessur am Department of Chemical Engineering, Massachusettes Institute of Technology (Prof. Dr. Robert Langer)
- seit 2023: Co-Editor-in-Chief beim European Journal of Pharmaceutics and Biopharmaceutics
- seit 2013: Co-Editorin beim European Journal of Pharmaceutics and Biopharmaceutics
- 2013: Habilitation im Fachgebiet Pharmazeutische Technologie an der
Universit?t Regensburg - seit 2012: Akademische R?tin bzw. Oberr?tin am Lehrstuhl für Pharmazeutische Technologie der Universit?t Regensburg
- 2008 und 2009: Postdoktorandin am Department of Chemical Engineering, Massachusettes Institute of Technology (Prof. Dr. Robert Langer)
- 2005-2012: Postdoktorandin am Lehrstuhl für Pharmazeutische Technologie der Universit?t Regensburg
- 2002 – 2005: Promotion am Lehrstuhl für Pharmazeutische Technologie der Universit?t Regensburg (Prof. Dr. Achim G?pferich)
- 1996-2001:Pharmaziestudium an der Ruprecht-Karls-Universit?t Heidelberg
Forschung
The Breunig group develops innovative drug delivery systems for small drug molecules and biologics such as proteins and nucleic acids. The team works on the following topics:
Development of a nanoparticulate HIV vaccine
Delivery of antigens to draining lymph nodes is essential for a potent HIV vaccine. Therefore, we use silica nanoparticles (SiNPs) as delivery platform for the multimeric presentation of HIV?s Envelope (Env) immunogen. We optimize the site-specific coupling reaction to achieve virus-mimetic nanoparticles that are physico-chemically characterized regarding size, zeta potential and functionality of the antigen. The multivalent antigen presentation leads to an increased avidity to B cell receptors followed by a higher B cell activation. Together with our partners from the HIVacToGC consortium we also investigate the kinetics of Env delivery to the lymph nodes in vivo.
The SiNPs are a platform technology which is also transferred to other protein-based antigens like e.g. the receptor binding domain (RBD) of SARS-CoV-2.
? Clara Barbey
Mesoporous silica nanoparticles for the delivery of antigens and adjuvants
Mesoporous silica nanoparticles have (MSN) an extremely high specific surface area and thus the advantage over SiNPs that their degradation time can be tuned by the pore size. Together with the group of Prof. Mika Lindén were explore MSNs as delivery systems for antigens and adjuvants.
? Clara Barbey
Hydrogels for sustained release of nanoparticulate antigens
Immunization usually requires several visits to a doctor to receive full immune protection. However, this conventional prime boost vaccination regimen is not as efficient regarding eliciting an immune response compared to other kinetics of vaccine application. Therefore, we create hydrogels that release nanoparticulate vaccines with various kinetics over a prolonged time.
Figure taken from: doi: 10.1016/j.ijpharm.2024.124131
Nanoparticulate drug delivery systems for the treatment of primary open-angle glaucoma
Primary open-angle glaucoma is a neurodegenerative disease of the optic nerve and one of the leading causes of blindness worldwide. Pathologic changes in the anterior chamber of the eye are critical in the development of primary open-angle glaucoma because aqueous humor outflow is obstructed by the trabecular meshwork and Schlemm's canal. Conventional treatment with eye drops does not bring the sweeping success due to an extremely low bioavailability after topical application. In addition, the applied active substances do not intervene at the root cause of the disease. We are developing nanoparticulate drug delivery systems that transport active substances to the site of action in the trabecular meshwork and Schlemm's canal after intracameral application. Furthermore, the applied drugs like small interfering RNA directly interfere with the pathomechanism of primary open angle glaucoma and do not only act on symptoms of the disease. This project is a cooperation with Prof. Rudolf Fuchshofer .
Figure taken from doi: 10.1002/smll.201803239
Publikationen
Ver?ffentlichungen
bwin娱乐_bwin娱乐官网欢迎您@e Liste stellt eine Auswahl aller Publikationen von apl. Prof. Dr. Miriam Breunig dar (Artikel, Buchkapitel, Hochschulschriften und Patente ab 2008). Das vollst?ndige Verzeichnis k?nnen Sie auf dem Publikationsserver der Universit?t abrufen.
Publikationsverzeichnis von Prof. Dr. Miriam Breunig
